Compare CMC & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMC | SRRK |
|---|---|---|
| Founded | 1915 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 5.6B |
| IPO Year | 1994 | 2018 |
| Metric | CMC | SRRK |
|---|---|---|
| Price | $65.70 | $49.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 12 |
| Target Price | ★ $73.89 | $55.64 |
| AVG Volume (30 Days) | 1.2M | ★ 1.7M |
| Earning Date | 03-26-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.21% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.41 | N/A |
| Revenue | ★ $7,918,430,000.00 | N/A |
| Revenue This Year | $18.81 | N/A |
| Revenue Next Year | $6.82 | $544.77 |
| P/E Ratio | $27.45 | ★ N/A |
| Revenue Growth | ★ 25.57 | N/A |
| 52 Week Low | $41.17 | $27.07 |
| 52 Week High | $84.87 | $51.63 |
| Indicator | CMC | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 53.41 | 59.51 |
| Support Level | $56.26 | $42.52 |
| Resistance Level | $71.99 | N/A |
| Average True Range (ATR) | 2.13 | 2.10 |
| MACD | 1.09 | 0.41 |
| Stochastic Oscillator | 87.15 | 79.15 |
Commercial Metals Co is a manufacturer and supplier of early-stage construction materials, including steel reinforcing bars, concrete pipes, precast products, and soil stabilization solutions. It also produces merchant bar, steel fence posts, and wire rod, serving domestic and some international markets in Europe and Asia. Its products are used in infrastructure and building projects such as highways, bridges, airports, and commercial and residential buildings.
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.